More than 10 leading government and private hospitals have been enrolled for the trials, the company said in a regulatory exchange filing Glenmark Pharmaceuticals Ltd said Tuesday it has started phase 3 clinical trials in India for its generic antiviral drug favipiravir to treat mild to moderate covid-19 and expects to complete the study by August.
Drug controller general of India V.G. Somani had in late April approved Glenmark’s plan to conduct the trials. More than 10 leading government and private hospitals have been enrolled for the trials, the company said in a regulatory exchange filing.
Favipiravir is a generic version of Avigan of Japan’s Fujifilm Toyama Chemical Co. Ltd, a subsidiary of Fujifilm Corp. Favipiravir has shown some